E company news, Northeast Pharmaceutical (000597) announced on the evening of January 24, the company submitted the "carboprost tromethamine" API registration application passed the State Food and Drug Administration Drug Evaluation Center (CDE) approval. Carboprost tromethamine is a prostaglandin drug that is mainly suitable for miscarriages of 13 to 20 weeks of gestation and postpartum haemorrhage caused by uterine contractile flaccidity that is ineffective in conventional management. The company is the first manufacturer of carboprost tromethamine API approved by CDE in China.